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Background/Aims
S-isomer (S) pantoprazole is more bioavailable and less dependent on cytochrome 2C19 than is racemic pantoprazole. We aim to 
evaluate the efficacy and safety of 10 mg S-pantoprazole for treatment of non-erosive reflux disease (NERD).
Methods
In this phase 3, double-blind, randomized placebo controlled, multicenter study, 174 NERD patients were randomized to one of 
both treatment groups: 10 mg S-pantoprazole, or placebo once daily for 4 weeks. Symptoms and safety were assessed. The efficacy 
endpoints were complete relief of symptoms, > 50% improvement of all reflux symptoms and recurrence. 
Results
Eighty-eight patients were assigned to the S-pantoprazole group (25 males, mean 43.7 years old) and 86 to the placebo group 
(32 males, mean 43.0 years old), and 163 patients were subjected to full Analysis Set. A higher proportion of patients in the 
S-pantoprazole group had complete symptom relief (42.0 % [34/81] vs 17.1% [14/82], P < 0.001) and > 50% symptom responses 
(66.0% vs 50.0%, P = 0.010 for heartburn; 64.2% vs 28.0%, P = 0.010 for acid regurgitation; and 51.9% vs 30.5%, P = 0.03 for 
epigastric discomfort) compared to the placebo group. The factors associated with poor responsiveness to PPI were older age, female, 
greater body mass index, and severe baseline symptoms.
Conclusions
Low dose of S-pantoprazole (10 mg) for 4 weeks was more efficacious than placebo in providing reflux symptom relief in patients 
with NERD, especially acid regurgitation. More doses or longer periods of treatment with S-pantoprazole would be needed to 
completely eliminate symptoms.
(J Neurogastroenterol Motil 2021;27:223-230)
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Introduction  
All proton pump inhibitors (PPIs) are chiral compounds. Chi-
rality can introduce selectivity and specificity in terms of interactions 
with receptors or enzyme-binding sites. This may lead to variations 
in pharmacokinetic and pharmacodynamic properties, as well as 
differences in safety and toxicity profiles.1,2 The use of a single iso-
mer offers predictable pharmacokinetics and increased potency.3,4 
Esomeprazole, the S-enantiomer of omeprazole, dexrabeprazole, 
and dexlansoprazole are good examples of racemic PPI switches, 
which have the clinical advantages of increasing the homogeneity of 
the treatment response and providing better efficacy with compa-
rable safety compared with racemic compounds.5-7
Pantoprazole is a selective and long-acting PPI. S-pantopra-
zole, the optical S-isomer of pantoprazole, was developed for the 
treatment of acid-related disorders. This agent displays a similar 
mechanism of action to that of racemic pantoprazole and is a highly 
effective inhibitor of gastric acid secretion.8,9 S-pantoprazole is 
subject to less extensive first-pass metabolism than is pantoprazole, 
resulting in higher systemic bioavailability.10
A reduction of the therapeutic dosage by chiral purification de-
creases the metabolic load on the body. Animal studies have shown 
that S-pantoprazole is more potent (1.5-1.9 fold) and effective (3-4 
fold) than racemate in inhibiting gastric lesions in several preclinical 
models.9 S-pantoprazole is associated with less pronounced inter-
individual variation of intragastric pH and more effective and lon-
ger-lasting inhibition of gastric acid secretion in a human study11; 
therefore, it may be expected to produce a more consistent clinical 
response. S-pantoprazole (20 mg) was more effective than racemic 
pantoprazole (40 mg) in improving the symptoms of heartburn, 
acid regurgitation, and bloating and was equally effective in heal-
ing esophagitis.11 The relative risk reduction was 15-33%. Another 
study showed 20 mg S-pantoprazole was effective in healing reflux 
esophagitis compared to placebo.12 There has been no study on the 
efficacy of low-dose (10 mg) S-pantoprazole for the treatment of 
gastroesophageal reflux disease (GERD). 
We performed a multi-center, double-blind, randomized, 
placebo-controlled phase III trial to evaluate the effect and safety of 
10 mg S-pantoprazole in NERD patients and assessed the rate of 
recurrence after cessation of medication.
Materials and Methods  
Patients
Patients who met all of the following criteria were eligible to 
enter the study: men or women aged 19-75 years living in South 
Korea and being an outpatient who had been diagnosed with 
NERD. Patients had heartburn and/or acid regurgitation for at 
least 3 months occurring on at least 2 days per week. The absence 
of endoscopic erosive esophagitis was proven during the previous 
7 days at the time of screening. Patients who had experienced at 
least 1 symptom of heartburn or acid regurgitation above moderate 
intensity for at least 2 days during the previous 7 days at the time 
of screening were included. Baseline symptoms were assessed by 
reflux disease questionnaire (RDQ). The RDQ assesses the degree 
of upper gastrointestinal symptoms over the previous 7 days using a 
set of 6 items (2 items per symptom) relating to symptom frequency 
(0-5 point) and severity (0-5 point) on a 6-point Likert scale. If 
a person has experienced at least 1 symptom of heartburn or acid 
regurgitation above moderate intensity for at least 2 days during the 
previous 7 days, the frequency score and intensity score on RDQ 
are more than 3 points both. 
Patients with any one of the following conditions were ineli-
gible to enter the study: Zollinger-Ellison syndrome; GI bleeding; 
esophageal stricture; ulcer stenosis; pyloric stenosis; esophageal 
gastric varices; Barrett’s esophagus measuring > 3 cm; intractable 
ulcer; digestive ulcer perforation or malignancy on upper gastro-
intestinal endoscopy; clinically significant hepatic, renal, cardiovas-
cular, respiratory, endocrine, or central nervous system disorder; 
history of malignancy or psychiatric disorder; pregnant or nursing 
mother; history of allergy to any of the study drugs or their related 
compounds; clinically significant liver disease or renal disease; using 
antipsychotics, antidepressants, or anxiolytics; using a PPI, hista-
mine H2-blocker, prokinetic agent, or antacid within 14 days before 
screening; or persistent daily use of non-steroidal anti-inflammatory 
drugs or aspirin during the study period.
Study Design 
Randomization, treatment, and follow-up 
This phase III multicenter study was involving 6 tertiary uni-
versity hospitals in South Korea. This was a multicenter, prospec-
tive, randomized, double-blind, placebo-controlled trial to assess 
effect and safety of 10 mg S-pantoprazole once daily for 4 weeks 
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compared to placebo in patients with NERD. The protocol for this 
study was approved by the institutional review boards at each insti-
tute according to the Declaration of Helsinki and the International 
Congress on Harmonization of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use—Good Clinical Prac-
tice guidelines (Approval No. KC14MDMT0431). All patients 
provided written informed consent. This study was performed 
with the approval of the Korean Food and Drug Administration 
(Approval No. LTP10_KR_1301). The study was registered with 
ClinicalTrials.gov under the number NCT02274961 (Study title: 
S-pantoprazole 10 mg Phase III Clinical Study). 
Ahn-Gook Pharmaceuticals Co, Ltd, Seoul, Korea, carried out 
centralized randomization and allocation to 10 mg S-pantoprazole 
or placebo group at a 1:1 ratio. All randomization information was 
securely stored and could be accessed by authorized personnel only. 
A double-dummy method, using matching 10 mg S-pantoprazole 
and placebo tablets, was employed to ensure that the study was 
double blinded with key codes kept off site by an external data man-
ager. All medications were provided in sealed boxes and supplied 
by the medication supervisor to ensure blinded allocation. Study 
patients were instructed to take 2 tablets, 10 mg S-pantoprazole and 
1 placebo once daily before eating breakfast. Patients returned for a 
study visit after 4 weeks of treatment and underwent reflux symp-
tom assessment (heartburn and/or acid regurgitation). Physical 
examination including assessment of vital signs, laboratory evalu-
ation of safety (including a serum pregnancy test for all females), 
collection and/or dispensing of the study drug, and assessment of 
concomitant medications and adverse events (AEs). In patients 
whose reflux symptoms had resolved after 4 weeks, the rate of reflux 
symptom recurrence was reassessed at 4 weeks after cessation of the 
medication. Medication compliance was monitored by counting the 
number of tablets remaining in the packet. 
Outcome parameters used to assess efficacy 
The primary efficacy endpoint was complete relief of reflux 
symptoms (heartburn and/or acid regurgitation). Complete relief 
of reflux symptoms was defined as the absence of any reflux symp-
toms (heartburn or acid regurgitation) within the past 7 days at 
the 4-week time point, as assessed by reflux disease questionnaire 
(RDQ) score. The RDQ is a self-administered questionnaire de-
signed to assess the frequency and severity of upper gastrointestinal 
symptoms over the previous week and to facilitate the diagnosis of 
GERD in primary care.13 The RDQ assesses the presence of these 
symptoms over the previous 7 days using a set of 6 items (2 items 
per symptom) relating to symptom frequency and severity (12 items 
total). RDQ are scored between 0 and 5 for each item of frequency 
and intensity. RDQ was validated in Korean GERD patients.14 
Secondary efficacy endpoints were improvement of reflux 
symptoms and rate of reflux symptom recurrence at 4 weeks af-
ter cessation of the medication in patients whose symptoms were 
resolved at 4 weeks. For evaluation of symptom improvement, we 
assessed the mean RDQ scores of each reflux symptom (heartburn 
and acid regurgitation) and the sum of the mean RDQ scores 
of these 2 symptoms at baseline and at 4 weeks. Improvement of 
symptoms was defined as a decrease in the RDQ score from base-
line. The symptom responses were compared both within a group 
and between groups. Each group compared Δ symptom scores 
between baseline and 4 weeks (intragroup analysis). The degree of 
symptom responses was compared between the placebo group and 
the s-pantoprazole group (intergroup analysis).
Safety Assessment
Safety was evaluated based on laboratory evaluations, physical 
examinations, and vital signs. Patients were also monitored for AEs 
from the day of signing the informed consent form until 30 days 
after the last day of study drug administration; the severity of each 
AE and its causal relationship to the study medication were evalu-
ated. All AEs that occurred after the patient signed the informed 
consent form were recorded (treatment-emergent AEs). The inves-
tigator rated the severity of each AE and assessed its relationship to 
the study drug.
Sample Size Calculation 
To determine the number of test subjects required to carry out 
this clinical trial, it was decided that: (1) superiority test; (2) level of 
significance, α = 0.025; (3) the error (β) of Class II was 0.2 and 
the power of the test was remained at 80%; (4) the proportion of S-
pantoprazole group and placebo group = 1:1; and (5) the rate of 
loss of reflux symptoms was assumed as 33.9% in the S-pantopra-
zole group and 13.7% in the placebo group, and the reference value 
for the loss rate was based on the Full Analysis Set (FAS) group’s 
response rate for the medical review of NDA 21-153 (nexium).15 
The required number of subjects was calculated to be 69 per group. 
Considering a 20% of dropout rate, 87 people per group were fi-
nally set as the target number of test subjects. 
Data Analysis 
The data were analyzed in 3 main forms: Safety Analysis, FAS 
Analysis, and Per Protocol Set (PPS) Analysis. The Safety Analysis 
included all subjects who were administered the study drugs at least 
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once. The FAS population included all patients who received a 
study drug at least once, in whom could obtain data on the primary 
efficacy endpoints after the study drugs were administered. The 
PPS population included all patients in the FAS with an evaluable 
primary endpoint who were randomized to a study treatment, com-
pleted their study treatment, and had no major protocol deviation. 
For the data on efficacy, in principle, the FAS analysis was the main 
analysis method, and additional PPS analysis was performed. For 
demographic data and data on safety, the Safety Analysis was the 
main analysis method.
Statistical Methods
All statistical analyses were done using StatView software for 
Windows (version 9.3; SAS Institute, Cary, NC, USA) in accor-
dance with the statistical analysis plan. For continuous variables, 
the values are expressed as number of participants, mean, standard 
deviation, median, minimum, and maximum. For categorical vari-
ables, the values are presented as frequency and percentage. The 
results were analysed using Fisher’s exact test (two-sided) for differ-
ences in proportions and Friedman’s test (nonparametric repeated-
measures ANOVA) for comparison of between-day scores (variation 




This study was conducted at 6 tertiary university hospitals be-
tween October 2015 and November 2016. A total of 174 patients 
recruited were randomized to the S-pantoprazole (n = 88) or pla-
cebo (n = 86) group. Patient disposition is shown in Figure. Eight 
patients in the S-pantoprazole group and 4 in the placebo group 
discontinued the study prematurely. The reasons for premature dis-
continuation were protocol violation (n = 3), loss to follow-up (n = 
3), AEs (n = 3), and withdrawal of consent (n = 3). A total of 162 
patients including 80 patients in the S-pantoprazole group and 82 
in the placebo group completed the study. FAS analysis was done in 
81 patients in S-pantoprazole group and 82 in the placebo group. 
PPS analysis was done in 75 patients in the S-pantoprazole group 
and 73 patients in the placebo group. The baseline demographic 
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Table 1. Baseline Demographics of S-pantoprazole and Placebo 
Groups (Safety Set) 
Dermographics S-pantoprazole Placebo P-value 
Number of patients 86 85
Gender (M:F) 25:61 32:53 0.230
Age (mean ± SD, yr) 43.7 ± 15.0 43.0 ± 13.1 0.770
BMI (mean ± SD, kg/m2) 22.3 ± 2.8 23.3 ± 3.7 0.037
Smoker 15 (17.4%) 10 (11.8%) 0.063
Alcohol 39 (45.3%) 43 (50.6%) 0.560
M, male; F, female; BMI, body mass index.
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variables of the 2 groups are shown in Table 1. There were no sig-
nificant differences in any of the baseline characteristics between the 
2 groups, with the exception of a higher body mass index (BMI) in 
the placebo group.
Symptom Responses of Reflux Symptoms at 4 Weeks
After 4 weeks of treatment, reflux symptoms had resolved in a 
41.98% (95% CI, 31.09-53.46; 34/81) of patients in the S-panto-
prazole group compared with 17.07% (95% CI, 9.66-26.98; 14/82) 
of the placebo group (P < 0.01).
A larger percentage of the S-pantoprazole group had a > 50% 
higher rate of improvement in all reflux symptoms than the pla-
cebo group (66.0% vs 50.0%, P = 0.010 for heartburn; 64.2% vs 
28.0%, P = 0.010 for acid regurgitation; and 51.9% vs 30.5%, P 
= 0.030 for epigastric discomfort). A higher percentage of the S-
pantoprazole group showed complete resolution of symptoms than 
the placebo group (56.8% vs 34.1%, P = 0.010 for heartburn; 
48.1% vs 17.1%, P = 0.010 for acid regurgitation; and 34.6% vs 
22.5%, P = 0.030 for epigastric discomfort) at 4 weeks. The de-
gree of improvement was greatest for acid regurgitation, followed 
by epigastric discomfort and heartburn.
Intergroup and Intragroup Analyses of Individual 
Symptoms
In the intragroup analysis, heartburn, acid regurgitation and 
epigastric discomfort significantly improved in each S-pantoprazole 
and placebo group after 4 weeks of treatment (P < 0.001). In the 
intergroup analysis, the degree of improvement in heartburn, acid 
regurgitation and epigastric discomfort after treatment was much 
better in the S-pantoprazole group than in the placebo group in all 
symptoms (Table 2).
Recurrence Rate
The rate of recurrence of reflux symptom at 4 weeks after ces-
sation of the medication was evaluated. 9.09% (3/33) of patients 
in the S-pantoprazole group were found to have recurrence, lower 
than the 14.29% (2/14) in the placebo group, however, the dif-
ference between the 2 groups was not statistically significant (P= 
0.627). Similar results were obtained when all 148 patients were 
subjected to a PPS analysis. 
Table 2. Improvement of Symptoms After 4 Weeks of Treatment in S-pantoprazole and Placebo Groups (the Secondary Endpoint)
Symptoms
S-pantoprazole (n = 81) Placebo (n = 82)
P-valuea
Baseline 4 wk Δsymptom score Baseline 4 wk Δsymptom score
Heartburn 2.82 ± 1.18 0.79 ± 1.12 –2.12 ± 1.42 2.70 ± 1.33 1.29 ± 1.42 –1.41 ± 1.59 0.005
Acid regurgitation 3.08 ± 1.17 0.86 ± 1.06 –2.22 ± 1.42 2.86 ± 1.38 1.91 ± 1.41 –0.95 ± 1.02 < 0.001
Epigastric discomfort 2.64 ± 1.39 1.07 ± 1.13 –1.58 ± 1.45 2.53 ± 1.42 1.64 ± 1.41 –0.90 ± 1.34 0.004
Overall reflux symptoms 2.95 ± 0.81 0.78 ± 0.89 –2.17 ± 1.12 2.78 ± 0.87 1.60 ± 1.21 –1.18 ± 1.05 < 0.001
Overall reflux symptom means sum of heartburn and acid regurgitation scores. 
aP-value means the statistical difference of Δsymptom score between S-pantoprazole and placebo groups per each symptom (intergroup difference). 
Values are expressed as mean ± SD.
Table 3. The Factors Associated With Reflux Symptom Resolution
Factors
S-pantoprazole Placebo
 Complete relief Incomplete relief 
P-value
 Complete relief Incomplete relief 
P-value
n = 34 n = 47 n = 14 n = 68
Baseline symptom score 11.38 ± 0.54 12.5 ± 0.51 < 0.001 9.93 ± 1.12 11.60 ± 0.43 < 0.001
Mean age (yr) 40.32 ± 2.60 44.81 ± 2.16 < 0.001 41.00 ± 3.64 42.87 ± 1.57 < 0.001
BMI (kg/m2) 21.97 ± 0.46 22.64 ± 0.47 < 0.001 22.81 ± 0.73 23.28 ± 0.42 < 0.001
Female gender 24/34 (70.6%) 34/47 (72.3%) < 0.05 8/14 (57.1%) 43/68 (63.2%) < 0.05
smoker 5/34 (14.8%) 9/47 (19.1%) < 0.001 4/14 (28.6%) 6/68 (8.9%) < 0.001
BMI, body mass index.
Values are expressed as mean ± SD.
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Factors Associated With Proton Pump Inhibitor 
Responsiveness
The factors associated with PPI responsiveness were evaluated. 
Thirty-four patients in the pantoprazole group and 14 in the pla-
cebo group whose symptoms had resolved were compared with pa-
tients whose symptoms had persisted. In both groups, as initial re-
flux symptoms were less severe, younger age, lower BMI, and male 
sex were associated with complete symptom resolution. In contrast, 
patients in both groups with reflux symptoms after 4 weeks tended 
to be older and female and to have a higher BMI and more severe 
baseline reflux symptoms (Table 3).
Safety
Safety was analyzed in 171 patients who received the study 
drug. Eleven patients (11/86, 12.8%) in the S-pantoprazole group 
and 11 patients (11/85, 12.9%) in the placebo group experienced 
AEs (P = 0.981). The rates of AEs were similar between the treat-
ment groups. With the exception of 1 patient in the S-pantoprazole 
group who was lost to follow up, all AEs resolved completely dur-
ing the study period. The majority of patients who experienced AEs 
had events that were mild or moderate in severity. The only serious 
AE experienced was 1 patient in the S-pantoprazole group who 
was admitted to the hospital because of a bile duct stone. The most 
frequently reported treatment-related AEs were gastrointestinal in 
both groups (n = 9). One AE in the S-pantoprazole group (1.2%) 
and 3 in the placebo group (3.5%) were considered to be related 
to the study drug (P = 0.374), and there were no serious adverse 
drug reactions in either group. One patient in the S-pantoprazole 
group and 2 in the placebo group discontinued the study drugs, 
primarily due to AEs.
Discussion  
This study aimed to assess the efficacy and safety of 10 mg 
S-pantoprazole for symptom control in NERD patients in com-
parison with a placebo. Of the patients, 42.0% (34/81) experienced 
complete relief of reflux symptoms after 4 weeks of S-pantoprazole 
treatment, compared with 17.0% (14/82) who received the placebo. 
The symptom loss rate was higher than initially expected in both the 
S-pantoprazole and placebo groups. S-pantoprazole was superior 
to placebo for control of all reflux symptoms, 66.0%, 64.2%, and 
51.9% of S-pantoprazole group showed a > 50% relief of heart-
burn, acid regurgitation, and epigastric discomfort, respectively, 
compared to 50.0%, 28.0%, and 30.5% for the placebo group. 
S-pantoprazole, has higher systemic bioavailability and less pro-
nounced inter-individual variation in the control of intragastric pH, 
it may be expected to produce a more consistent clinical response 
than would racemic pantoprazole.16 Several studies have evaluated 
20 mg S-pantoprazole in reflux esophagitis patients.11,12 Half dose 
or low dose PPI is usually used as the maintenance treatment. We 
studied low dose (10 mg) S-pantoprazole for initial treatment of 
NERD.
In this study, complete relief of reflux symptoms was achieved 
in 42.0% (34/81) of patients. Several meta-analyses conducted in 
NERD patients have reported similar results.17-19 In 1 meta-anal-
ysis, the overall rate of symptom relief by PPIs in NERD patients 
was 51.4%.15 The PPI responsiveness depends on the definition 
of NERD used, whether 24-hour esophageal pH study was used 
or not to diagnose NERD.18 We defined NERD as symptomatic 
GERD with normal endoscopy findings without pH testing. A 
meta-analysis showed that if the NERD was defined as the same 
as our study, the pooled estimate of complete symptom relief after 4 
weeks was 0.49 (95% CI, 0.44-0.55) and pooled estimate of partial 
symptom relief was 0.65 (95% CI, 0.61-0.69).17 If the response had 
been defined as > 50% symptom relief rate instead of complete 
relief, heartburn and acid regurgitation would have been considered 
relieved in 56.0% and 65.0% of patients, respectively. These values 
are similar to the 66.0% and 64.2% of > 50% symptom response 
rates in this study. In this study, acid regurgitation was more respon-
sive than heartburn and epigastric discomfort.
We defined NERD as symptomatic GERD with normal en-
doscopy findings without pH testing. We used the validated RDQ, 
as it has been shown to increase the sensitivity of the GERD diag-
nosis.13 The study population may have included functional heart-
burn (if acid exposure is normal with no symptom reflux association 
on pH-impedance testing on PPI), and reflux hypersensitivity 
patients (if acid exposure is normal with positive symptom reflux 
association on pH impedance testing on PPI), which may have led 
to significantly underestimation of PPI efficacy. Definition of these 
phenotypes could be important, and functional overlap situations 
may have therapeutic approaches different from true refractory 
GERD.18 Functional heartburn is a functional disorder in which 
symptoms are related to psychological factors and disturbed visceral 
perception, not related to refluxate of gastric contents. Functional 
heartburn is found in approximately 50% of PPI nonresponders 
and in 25% of PPI responders.19-21 Therapies for functional heart-
burn remain largely empiric and may be tailored to the proposed 
pathophysiology of the condition, presumed mechanism of drug 
action, and underlying psychosocial issues.
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The rate of recurrence at 4 weeks after reflux symptom resolu-
tion in the S-pantoprazole group was 9.2%, lower than the 14.3% of 
the placebo group, but the difference was not statistically significant. 
On demand by the patients therapy was not done. Therefore, 4 
weeks of treatment may be short to prevent recurrence effectively. 
Standard dose PPI treatment for treatment of NERD is not yet 
covered by the Korea National Health Insurance which still recom-
mends half dose PPI treatment rather than standard dose PPI for 
NERD patients as the initial and maintenance treatment. However, 
this study suggests the half dose PPI may be suboptimal to prevent 
recurrence effectively even though longer medication duration may 
act to obtain optimal acid suppression in NERD patients.
The factors associated with PPI responsiveness in NERD pa-
tients were evaluated. In both groups, patients whose reflux symp-
toms remained tended to be older and female and to have a higher 
BMI and more severe baseline reflux symptoms. More severe 
symptomatic patients may need a higher dose or longer duration of 
therapy. Obesity can influence the symptom response and recur-
rence rate. Old age and female sex have been reported to be associ-
ated with PPI non-responsiveness.22-25 In addition, psychological 
factors can influence the response to PPIs even though it was not 
evaluated by questionnaire in this study.
In conclusion, low dose of S-pantoprazole (10 mg) for 4 weeks 
was more efficacious than placebo in providing reflux symptom re-
lief in patients with NERD, especially acid regurgitation. The com-
plete symptom resolution was achieved in 42.0% of the S-pantopra-
zole group. Increased doses or longer periods of treatment with S-
pantoprazole would be needed to completely eliminate symptoms.
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